This article is a correction to:
Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines
Allegra Peletta
Aurélie Marmy1
Alcidia Ramos Barros
Žiga Jakopin
Gerrit Borchard- 1Section of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, Geneva, Switzerland
- 2Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
A Corrigendum on
Preliminary results on novel adjuvant combinations suggest enhancement immunogenicity of whole inactivated pandemic influenza vaccines
by Peletta A, Marmy A, Guzelj S, Ramos Barros A, Jakopin Ž and Borchard G (2024). Front. Drug Deliv. 4:1382266. doi: 10.3389/fddev.2024.1382266
In the published article, there was an error in the Funding statement. “Swiss National founding, grant no: 20 IZCOZ0_182947” was included incorrectly. Instead, it should appear as “Swiss National Science Foundation (SNF), grant no: IZCOZ0_182947.” The correct Funding statement appears below.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Swiss National Science Foundation (SNF), grant no: IZCOZ0_182947.
In the published article, there was an error. The following sentence was mistakenly not included in the Acknowledgments: “The research was funded by Swiss National Science Foundation (SNF), grant no: IZCOZ0_182947.”
The correct Acknowledgments appears below:
“The authors would like to warmly thank the Vaccine Formulation Institute, particularly Dr. Nicolas Collin, Dr. Stéphanie Romand, Dr. Céline Lemoine, Dr. Livia Brunner, and Florian Gobet for their huge contribution to the project. They specifically thank Dr. Romand for the development of the LC-MS protocol, M. Gobet for his help with animal studies, and Dr. Lemoine and Dr. Brunner for their help in building the project as well as advice on multiple occasions. The research was funded by Swiss National Science Foundation (SNF), grant no: IZCOZ0_182947.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pandemic influenza vaccine, adjuvant, hybrid PLGA nanoparticle, tomatine saponin, NOD2 agonists, formulation, immunogenicity
Citation: Peletta A, Marmy A, Guzelj S, Ramos Barros A, Jakopin Ž and Borchard G (2024) Corrigendum: Preliminary results on novel adjuvant combinations suggest enhancement immunogenicity of whole inactivated pandemic influenza vaccines. Front. Drug Deliv. 4:1519969. doi: 10.3389/fddev.2024.1519969
Received: 30 October 2024; Accepted: 03 December 2024;
Published: 16 December 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Peletta, Marmy, Guzelj, Ramos Barros, Jakopin and Borchard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Allegra Peletta, YWxsZWdyYS5wZWxldHRhQHVnZW50LmJl